Policy & Regulation
PredictImmune Names Clark as Chief Technology Officer
15 November 2019 - - UK-based immune-mediated inflammatory disease specialist PredictImmune has named James Clark as chief technology officer, the company said.
Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialisation of diagnostic and therapeutic products.
PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn's and ulcerative colitis (IBD).
Prior to EnteroBiotix James' roles included vice president of Clinical Laboratory Operations at Inivata, chief technology officer at Enterome, vice president of Research and Development at MDxHealth SA and chief operating officer at Response Genetics (IPO: NASDAQ).
This latest appointment to the PredictImmune senior team follows a wave of recent announcements including the start of a jointly sponsored study with the Crohn's and Colitis Foundation to validate PredictSURE IBD in the US market, and an announcement that PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical to promote and provide PredictSURE IBD throughout North America.
Earlier in the year PredictImmune confirmed a strategic agreement with French diagnostic specialist, Theradiag, to commercialise PredictSURE IBD in France, Belgium, Luxembourg, Switzerland and the Maghreb countries.
This flurry of activity follows in the wake of the launch of PredictSURE IBD in the UK and Ireland in April this year.
Login
Username:

Password:


Related Headlines